Top

Published in:

Open Access 15-04-2024 | Angiography | Research

Could Pan-Immune-Inflammation Value be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?

Authors: Mustafa Kaplangoray, Kenan Toprak, Edhem Deveci, Cuneyt Caglayan, Ebru Şahin

Published in: Cardiovascular Toxicology | Issue 5/2024

Abstract

Inflammation plays a key role in the pathogenesis of the coronary slow flow phenomenon (CSFP). The newly developed inflammatory marker, pan-immune-inflammation value (PIV), is associated with adverse cardiovascular events. This study investigated the predictive value of PIV for diagnosing CSFP in comparison to other inflammation-based markers. A total of 214 patients, 109 in the CSFP group and 105 in the normal coronary flow (NCF) group, were retrospectively included in the study. Coronary flow was calculated using the Thrombolysis in Myocardial Infarction frame count method. In addition to PIV, other inflammatory markers such as neutrophil–lymphocyte ratio, platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated for the patients. The average age of patients was 50.3 ± 8.4, with a male ratio of 55.1%. Compared to the NCF group, patients in the CSFP group had higher levels of hyperlipidemia, glucose, triglyceride, NLR, PLR, SII, and PIV, while their high-density lipoprotein cholesterol (HDL-C), was lower (p < 0.05). Logistic regression analysis demonstrated that HDL-C, glucose, triglyceride, and PIV were independent predictor factors for CSFP (p < 0.05). PIV is a strong and independent predictor factor for CSFP and superior in predicting CSFP compared to other inflammatory markers.

Beltrame, J. F. (2012). Defining the coronary slow flow phenomenon. Circulation Journal, 76, 818–820.CrossRefPubMed

Tambe, A. A., Demany, M. A., Zimmerman, H. A., & Mascarenhas, E. (1972). Angina pectoris and slow flow velocity of dye in coronary arteries—A new angiographic finding. American Heart Journal, 84, 66–71.CrossRefPubMed

Askin, L. (2021). Evaluation of heart rate recovery index in patients with coronary slow flow: Preliminary results. European Review for Medical and Pharmacological Sciences, 25, 7941–7946.PubMed

Chalikias, G., & Tziakas, D. (2021). Slow coronary flow: Pathophysiology, clinical implications, and therapeutic management. Angiology, 72, 808–818.CrossRefPubMed

Mosseri, M., Yarom, R., Gotsman, M. S., & Hasin, Y. (1986). Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation, 74, 964–972.CrossRefPubMed

Sezgin, A. T., Sgrc, A., Barutcu, I., Topal, E., Sezgin, N., Ozdemir, R., Yetkin, E., Tandogan, I., Kosar, F., Ermis, N., Yologlu, S., Barskaner, E., & Cehreli, S. (2003). Vascular endothelial function in patients with slow coronary flow. Coronary Artery Disease. https://doi.org/10.1097/00019501-200304000-00008CrossRefPubMed

Kalay, N., Aytekin, M., Kaya, M. G., Ozbek, K., Karayakalı, M., Söğüt, E., Altunkas, F., Oztürk, A., & Koç, F. (2011). The relationship between inflammation and slow coronary flow: Increased red cell distribution width and serum uric acid levels. Türk Kardiyoloji Dernegi Arsivi, 39, 463–468.CrossRefPubMed

Yildiz, A., Yilmaz, R., Demirbag, R., Gur, M., Bas, M. M., & Erel, O. (2007). Association of serum uric acid level and coronary blood flow. Coronary Artery Disease. https://doi.org/10.1097/MCA.0b013e3282f0a2a7CrossRefPubMed

Pekdemir, H., Polat, G., Cin, V. G., Çamsari, A., Cicek, D., Akkus, M. N., Doven, O., Katircibası, M. T., & Muslu, N. (2004). Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. International Journal of Cardiology, 97, 35–41.CrossRefPubMed

10.

Kantarci, M., Gündogdu, F., Doganay, S., Duran, C., Kalkan, M. E., Sagsoz, M. E., Kucuk, O., Karakaya, A., Kucuk, A., & Akgün, M. (2011). Arterial bending angle and wall morphology correlate with slow coronary flow: Determination with multidetector CT coronary angiography. European Journal of Radiology, 77, 111–117.CrossRefPubMed

11.

Aşkın, L., Çetin, M., Türkmen, S., Tasolar, M. H., & Aktürk, E. (2018). Quantitative ultrasound measurements of common carotid artery blood flow velocity patterns in patients with coronary slow flow. Journal of Human Rhythm, 4, 117–125.

12.

de Moura Monteiro Júnior, J. G., de Oliveira Cipriano Torres, D., & Filho, D. C. S. (2019). Hematological parameters as prognostic biomarkers in patients with cardiovascular diseases. Current Cardiology Reviews, 15, 274–282.CrossRef

13.

Çetin, M., Kiziltunc, E., Elalmış, Ö. U., Çetin, Z. G., Demirçelik, M. B., Çiçekçioğlu, H., Kurtul, A., Özkan, S., Avan, C. M., Örnek, E., & Ulusoy, F. V. (2016). Predictive value of neutrophil lymphocyte ratio and platelet lymphocyte ratio in patients with coronary slow flow. Acta Cardiological Sinica, 32, 307–312.

14.

Kopetz, V., Kennedy, J., Heresztyn, T., Stafford, I., Willoughby, S. R., & Beltrame, J. F. (2012). Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology, 121, 197–203.CrossRefPubMed

15.

Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., & Stătescu, C. (2023). Assessment of inflammatory hematological ratios (NLR, PLR, MLR, LMR and monocyte/HDL–cholesterol ratio) in acute myocardial infarction and particularities in young patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241814378CrossRefPubMedPubMedCentral

16.

Guven, D. C., Sahin, T. K., Erul, E., Kilickap, S., Gambichler, T., & Aksoy, S. (2022). The association between the pan-immune-inflammation value and cancer prognosis: A systematic review and meta-analysis. Cancers. https://doi.org/10.3390/cancers14112675CrossRefPubMedPubMedCentral

17.

Murat, B., Murat, S., Ozgeyik, M., & Bilgin, M. (2023). Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction. European Journal of Clinical Investigation, 53, e13872.CrossRefPubMed

18.

Bayramoğlu, A., & Hidayet, Ş. (2023). Association between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 83, 384–389.CrossRefPubMed

19.

Gibson, C. M., Cannon, C. P., Daley, W. L., Dodge, J. T., Alexander, B., Marble, S. J., McCabe, C. H., Raymond, L., Fortin, T., Poole, W. K., & Braunwald, E. (1996). TIMI frame count. Circulation, 93, 879–888.CrossRefPubMed

20.

Kayapinar, O., Ozde, C., & Kaya, A. (2019). Relationship between the reciprocal change in inflammation-related biomarkers (fibrinogen-to-albumin and hsCRP-to-albumin ratios) and the presence and severity of coronary slow flow. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029619835383CrossRefPubMedPubMedCentral

21.

Bhat, T., Teli, S., Rijal, J., Bhat, H., Raza, M., Khoueiry, G., Meghani, M., Akhtar, M., & Costantino, T. (2013). Neutrophil to lymphocyte ratio and cardiovascular diseases: A review. Expert Review of Cardiovascular Therapy, 11, 55–59.CrossRefPubMed

22.

Kaplangoray, M., Toprak, K., Başanalan, F., Palice, A., Aydın, C., Demirkıran, A., & Cekici, Y. (2023). Investigação da Relação entre Índice de Triglicerídeos-Glicose e Fluxo Lento Coronariano Um Estudo Retrospectivo de Caso-Controle. Arquivos Brasileiros de Cardiologia. https://doi.org/10.36660/abc.20220679CrossRefPubMedPubMedCentral

23.

Dai, X.-T., Kong, T.-Z., Zhang, X.-J., Luan, B., Wang, Y., & Hou, A.-J. (2022). Relationship between increased systemic immune-inflammation index and coronary slow flow phenomenon. BMC Cardiovascular Disorders, 22, 362.CrossRefPubMedPubMedCentral

24.

Guven, D. C., Erul, E., Yilmaz, F., Yasar, S., Yildirim, H. C., Ercan, F., Kaygusuz, Y., Cayiroz, K., Ucdal, M. T., Yesil, F., Yazici, G., Cengiz, M., Gullu, I., & Aksoy, S. (2023). The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 280, 2471–2478.CrossRefPubMed

25.

Yeh, C.-C., Kao, H.-K., Huang, Y., Tsai, T.-Y., Young, C.-K., Hung, S.-Y., Lu, C.-Y., & Chang, K.-P. (2023). Discovering the clinical and prognostic role of pan-immune-inflammation values on oral cavity squamous cell carcinoma. Cancers. https://doi.org/10.3390/cancers15010322CrossRefPubMedPubMedCentral

26.

Zhang, F., Li, L., Wu, X., Wen, Y., Zhan, X., Peng, F., Wang, X., Zhou, Q., & Feng, X. (2023). Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis. Renal Failure, 45, 2158103.CrossRefPubMedPubMedCentral

27.

Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017). Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nature Reviews Cardiology, 14, 133–144.CrossRefPubMed

28.

Akkaya, S., & Cakmak, U. (2024). Association between pan-immune-inflammation value and coronary slow flow phenomenon in patients with angiographically normal coronary arteries. International Journal of Cardiology, 398, 131631.CrossRefPubMed

29.

Cetinkaya, Z., Kelesoglu, S., Tuncay, A., Yilmaz, Y., Karaca, Y., Karasu, M., Secen, O., Cinar, A., Harman, M., Sahin, S., Akin, Y., & Yavcin, O. (2024). The role of pan-immune-inflammation value in determining the severity of coronary artery disease in NSTEMI patients. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13051295CrossRefPubMedPubMedCentral

30.

Afsin, A., Kaya, H., Suner, A., Uzel, K. E., Bursa, N., Hosoglu, Y., Yavuz, F., & Asoglu, R. (2021). Plasma atherogenic indices are independent predictors of slow coronary flow. BMC Cardiovascular Disorders, 21, 608.CrossRefPubMedPubMedCentral

31.

Dobiášová, M., Frohlich, J., Šedová, M., Cheung, M. C., & Brown, B. G. (2011). Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of Lipid Research, 52, 566–571.CrossRefPubMedPubMedCentral

32.

Aciksari, G., Cetinkal, G., Kocak, M., Atici, A., Celik, F. B., & Caliskan, M. (2022). The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow-flow phenomenon. The International Journal of Cardiovascular Imaging, 38, 5–13.CrossRefPubMed

33.

Sanati, H., Kiani, R., Shakerian, F., Firouzi, A., Zahedmehr, A., Peighambari, M., Shokrian, L., & Ashrafi, P. (2016). Coronary slow flow phenomenon: Clinical findings and predictors. Research in Cardiovascular Medicine. https://doi.org/10.5812/cardiovascmed.30296CrossRefPubMedPubMedCentral

34.

Khalfallah, M., Maria, D. A., & Allaithy, A. (2022). Impact of stress hyperglycemia on no-reflow phenomenon in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Global Heart, 17, 23.CrossRefPubMedPubMedCentral

35.

Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H., & Yasue, H. (1999). Hyperglycemia rapidly suppresses flow-mediated endothelium—Dependent vasodilation of brachial artery. Journal of the American College of Cardiology, 34, 146–154.CrossRefPubMed

36.

Vehkavaara, S., Seppälä-Lindroos, A., Westerbacka, J., Groop, P. H., & Yki-Järvinen, H. (1999). In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care, 22, 2055–2060.CrossRefPubMed

37.

Anastasiou, E., Lekakis, J. P., Alevizaki, M., Papamichael, C. M., Megas, J., Souvatzoglou, A., & Stamatelopoulos, S. F. (1998). Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care, 21, 2111–2115.CrossRefPubMed

38.

Binak, E., Gunduz, H., Sahin, M., Kurtoglu, N., & Dindar, I. (2006). The relation between impaired glucose tolerance and slow coronary flow. International Journal of Cardiology, 111, 142–146.CrossRefPubMed

39.

Xia, S., Deng, S.-B., Wang, Y., Xiao, J., Du, J.-L., Zhang, Y., Wang, X.-C., Li, Y.-Q., Zhao, R., He, L., Xiang, Y.-L., & She, Q. (2011). Clinical analysis of the risk factors of slow coronary flow. Heart and Vessels, 26, 480–486.CrossRefPubMed

Title: Could Pan-Immune-Inflammation Value be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?
Authors: Mustafa Kaplangoray
Kenan Toprak
Edhem Deveci
Cuneyt Caglayan
Ebru Şahin
Publication date: 15-04-2024
Publisher: Springer US
Keyword: Angiography
Published in: Cardiovascular Toxicology / Issue 5/2024
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-024-09855-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Could Pan-Immune-Inflammation Value be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Acute High-Output Heart Failure with Pulmonary Hypertension and Severe Liver Injury Caused by Amlodipine Poisoning: A Case Report

N-acetylcysteine Protects Against Myocardial Ischemia–Reperfusion Injury Through Anti-ferroptosis in Type 1 Diabetic Mice

Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: “What Are the Tools Needed for the Job?” and “Do We Have Them?”

Identification of Circulating Inflammatory Proteins Associated with Calcific Aortic Valve Stenosis by Multiplex Analysis

Opioids-Induced Long QT Syndrome: A Challenge to Cardiac Health

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page